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Abstract Shiga-like toxin 1 (SLT) from Escherichia coli
0157:H7 enters mammalian cells by endocytosis from the cell
surface to the endoplasmic reticulum before translocating into
the cytosol. Here, SLT was engineered at its N- or C-terminus to
carry a peptide derived from influenza virus Matrix protein for
delivery to major histocompatibility complex (MHC) class I
molecules. We show that SLT N-Ma was capable of sensitising
cells for lysis by appropriate cytotoxic T-lymphocytes whilst no
killing of SLT-resistant cells was observed. Our results
demonstrate that peptide was liberated intracellularly and that
retrograde transport of a disarmed cytotoxic protein can
intersect the MHC class 1 presentation pathway.
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1. Introduction
Peptides, derived by proteasomal degradation of proteins in
the cytosol, are normally translocated to the endoplasmic re-
ticulum (ER) by peptide transporters associated with antigen
processing (TAPs) before they associate with empty major
histocompatibility complex (MHC) class 1 molecules in the
ER lumen. The complexes are then transported through the
secretory pathway to the plasma membrane where they can be
recognised by CD8+ T cells (CTL) in a process which ulti-
mately leads to the death of the antigen-presenting cell [1].
Such CTL responses are an important part of the immune
response to viral infections and tumours [2^4] and consider-
able e¡ort is now being expended in developing potential
vaccine protocols that might a¡ord protective immunity
against a variety of infectious agents and other immune dis-
orders.
A variety of approaches to generate protective CTLs are
being tried (see [5] for review). Live viral vaccines, however,
being potentially pathogenic, are risky to the recipient, where-
as direct immunisation with a viral protein tends to lead to
antigen endocytosis and a subsequent class II rather than class
I response. Here we show that a disarmed (catalytically inac-
tive) protein toxin, known to be endocytosed from the cell
surface to the ER lumen and then transferred to the cytosol
of eukaryotic cells, is an alternative potential vehicle for the
delivery of peptide epitopes in the MHC class I processing
pathway.
Shiga-like toxin 1 (SLT) from Escherichia coli 0157:H7 is a
Shiga toxin analogue comprising an enzymatic A chain (V32
kDa) non-covalently associated with a pentamer of B subunits
(7.6 kDa/subunit) [6]. The A chain becomes cleaved during
toxin uptake to generate the A1 (V29 kDa) and A2 (V3
kDa) fragments. The SLT1 holotoxin is a ribosome-inactivat-
ing enzyme that normally gains access to its substrates by
initially binding to globotriose-ceramide receptors (CD77)
on the surface of sensitive cells [7]. SLT1 belongs to a small
group of cytotoxic proteins, which includes cholera toxin (CT)
[8], whose productive cellular intoxication pathway is known
to involve endocytosis from the cell surface to the ER before
membrane transport to the cytosol. Intracellular tra⁄cking of
SLT1 has been studied in detail and its localisation in the ER
of sensitive cells has been visualised [9,10]. We therefore con-
structed modi¢ed holotoxins genetically fused to an in£uenza
virus epitope and investigated their abilities to generate a
CD8+ response in vitro.
2. Materials and methods
2.1. Materials
The majority of reagents used were obtained from BDH Chemicals
Ltd (UK), Fisons (USA) or Sigma (UK) and were of analytical grade
if available. K-[35S]dATP (1000 Ci/mmol), [35S]methionine (3000 Ci/
mmol), and Q-[32P]ATP (5000 Ci/mmol) were from Amersham, UK,
lactacystin was from Calbiochem (UK), ricin B chain from Inland
Laboratories (USA), and recombinant ricin-A chain was from Zeneca
Pharmaceuticals (UK). Phosphate-bu¡ered saline (PBS) was (137 mM
sodium chloride, 0.27 mM potassium chloride 10.4 mM disodium
hydrogen phosphate, 1.8 mM potassium dihydrogen phosphate).
HeLa and Vero cells were grown in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM) supplemented with 5% heat-inactivated foetal calf
serum, 2 mM glutamine, 50 IU/ml penicillin, 300 Wg/ml streptomycin.
SKmel-29 and HeLa-A2 cells were grown in RPMI 1640 medium
(supplemented with 10% heat inactivated foetal calf serum, 2 mM
glutamine, 50 IU/ml penicillin, 300 Wg/ml streptomycin) with the
latter containing 800 Wg/ml (powder weight) geneticin G-418 sulphate.
CTL clones were maintained in Iscove’s medium (5% human serum,
100 U/ml IL-2) and restimulated every 3 weeks. CTL (5U105) were
stimulated with matched peripheral blood lymphocytes (2U106) and
B cells (5U105) in 2 ml Iscove’s medium (5% human serum, 100 U/ml
IL-2, 5 Wg/ml pHA) and allowed to proliferate for 1 week, replacing
with fresh media.
2.2. Expression and puri¢cation of Shiga-like toxin-peptide chimeras
Recombinant SLT fusions were expressed in a 1-l culture of Esche-
richia coli TG2 cells harbouring pUC19 containing the SLT1 bicis-
tronic operon [11] during a 3-h induction with 1 mM isopropyl 1-thio-
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L-D-galactoside. Cells were harvested, resuspended in 20% (w/v) su-
crose, 300 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.5 mM MgCl2,
repelleted and resuspended in 10 ml 1 mM ice-cold Tris-HCl pH
7.5 to osmotically lyse the cells’ periplasm and release assembled
SLT1 oligomers. The resulting high-speed supernatant was ¢lter-steri-
lised and applied to a 1 ml synthetic globotriose-Sepharose a⁄nity
chromatography column equilibrated in PBS. SLT1 was subsequently
eluted with 6 M guanidine hydrochloride, immediately dialysed
against PBS overnight and selected samples were quanti¢ed and ana-
lysed by reducing SDS-PAGE.
2.3. Protein inhibition assays
HeLa-A2 cells were plated in £at-bottomed 96-well plates (1.5U104/
well) in RPMI+5% foetal calf serum, in a total volume of 150 Wl per
well. Cells were then incubated with various concentrations of SLT
proteins in quadruplicate, for 16 h at 37‡C before adding
[35S]methionine (1 WCi/well) and incubating for a further 2 h. Cell
proteins were precipitated by washing 3 times with 5% trichloroacetic
acid, and radioactivity measured by liquid scintillation counting. Pro-
tein synthesis was measured by the incorporation of [35S]methionine
into protein and a percentage calculated in relation to toxin-free con-
trol cells.
2.4. CTL assays
Matrix-speci¢c CTL were generated from peripheral blood lympho-
cytes puri¢ed from healthy volunteers. A CTL clone was isolated by
single cell sorting using HLA-A2/Matrix 58-66 tetramers [12] and used
as e¡ectors. Targets were HeLa cells stably transfected with HLA-A2
DNA (kindly provided by Dr H. Stauss, Hammersmith Hospital,
London). 1U106 HeLa-A2 cells were incubated with D167SLT-Ma
chimeras (20 ng/ml) overnight. Cells were then washed and labelled
with 51Cr (50 WCi) for 90 min at 37‡C, washed and incubated for a
further 3 h at 37‡C. Cells were then plated with CTLs at 5:1 and 2:1
e¡ector/target ratios and incubated for 4 h at 37‡C before 51Cr release
counting. HeLa A2 cells were treated with IFN-Q (100 U/ml) for 48 h
before the incubation with the toxin. As controls, HeLa-A2 cells were
infected for 90 min with 5 plaque-forming units (pfu) of vaccinia virus
encoding in£uenza Matrix (M1). Cells were then washed and allowed
to express in£uenza Matrix protein overnight prior to 51Cr labelling.
SKmel-29 cells were incubated with SLT N-Ma toxin as described
above and the ability of these cells to be sensitised for cytotoxicity
was determined using the A2 MAGE-3 peptide 271^279 (10 WM for
1 h). Target cells were then incubated with HLA-A2 MAGE-3 speci¢c
CTL (e¡ector/target ratios were 27:1 and 9:1). In some experiments
cells were incubated with 5 Wg/ml brefeldin A (BFA) for 1 h before
addition of toxin or M1, and BFA was maintained at this concen-
tration throughout the assay.
3. Results
A minigene encoding the in£uenza Matrix 58^66 (M58^66-
peptide GILGFVFTL, using the single-letter code) was genet-
ically fused with the 5P- or 3P-terminus of genomic DNA en-
coding the catalytic A chain of the toxin. The bicistronic
operon encoding SLT B chain and the modi¢ed A chain per-
mits expression of holotoxins designated SLT N-Ma or SLT
C-Ma, depending whether M58^66 is located at the N- or
C-terminus of the toxic A chain. The structures of the SLT-
peptide chimeras are shown schematically in Fig. 1. To sig-
ni¢cantly reduce the native cytotoxicity of the toxin portion,
an active site mutation (glutamate-167 to aspartate; E167D),
previously reported to cause a 1000-fold reduction in protein
synthesis-inactivating activity [13], was simultaneously cre-
ated. Recombinant holotoxins were puri¢ed to homogeneity
from E. coli by receptor-ligand based chromatography using
globotriose (K-D-galactose-(1C4)-L-D-galactose-(1C4)-L-D-
glucose-(1C)) coupled to a Sepharose matrix (an example is
shown in Fig. 2A). By denaturing SDS-PAGE, the peptide-
containing A chains were visually larger than native SLT A
chain (Fig. 2B), with molecular masses of 33148.47 þ 0.31 and
33148.08 Da þ 2.83 for SLT N-Ma and C-Ma respectively, as
determined by electrospray ionisation mass spectrometry. The
predicted molecular mass is 33148.58. Thus, the in£uenza Ma-
trix peptide (Ma) remained intact at the termini of the SLT A
chains during expression and subsequent puri¢cation.
To ensure that the presence of the peptide did not interfere
with normal tra⁄cking of the toxin moiety, M58^66 was con-
jugated to the wild type toxin. When applied to HeLa cells,
the peptide/wild type SLT was as potent as SLT without the
M58^66 (Fig. 2C) with an IC50 value (i.e. concentration of
toxin required to inhibit protein synthesis by 50%) of 0.01 ng/
ml. Furthermore, when cells were pre-treated with 5 Wg/ml
BFA to collapse the Golgi stack, the toxicity of wild type
SLT-carrying peptide was completely blocked (Fig. 2C).
This indicates that the uptake pathway of toxin chimeras
was identical to that of native toxin without antigenic peptide.
Peptide chimeras engineered using E167D SLT were, as ex-
pected, approximately 100-fold less active than native toxin in
direct assays on mammalian ribosomes in vitro [14] (data not
shown), and 1000-fold less toxic in vivo (IC50 10 ng/ml) (Fig.
2C), supporting the view that SLT can be signi¢cantly dis-
armed by the incorporation of a single mutation that is un-
likely to cause major structural perturbation.
Since HeLa cells do not express the required HLA-A2 hap-
lotype, we used HeLa cells stably transfected with HLA-A2
DNA and con¢rmed the A2 expression by FACS staining
(data not shown). HeLa-A2 cells treated with the SLT
N-Ma were sensitised for lysis by Matrix 58^66-speci¢c CTL
(Fig. 3). In contrast, no lysis was observed after addition of
the SLT C-Ma, even though it could be internalised by HeLa-
A2 cells (Fig. 2C). To demonstrate that HeLa-A2 cells were
capable of processing and presenting intracellular antigens, we
showed that infection with a vaccinia virus encoding in£uenza
Matrix protein sensitises them for lysis by in£uenza-speci¢c
CTL. Since a CTL clone was used rather than a CTL line, the
background killing against a wild type, non-recombinant vac-
cinia was negligible [15]. It is of interest that presentation of
the M58^66 epitope contained within the full length Matrix
Fig. 1. Schematic representation of SLT-peptide chimeras. SLT hol-
otoxin comprises a single A chain non-covalently associated with a
pentamer of B chains. Upon cellular uptake the A chain becomes
proteolytically cleaved at a furin recognition site (arrow) into an A1
fragment with catalytic activity and a C-terminal A2 fragment
which remains associated with the ¢ve B chains (for clarity here the
A2 fragment and the B chains are drawn apart) and disulphide
bonded with A1. D167 refers to a catalytic site mutation. In£uenza
Matrix peptide, M58^66 (GILGFVFTL, in single letter code) is de-
noted by the zig-zag at either the N- or C-terminus of the SLT A
chain.
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protein and the SLT N-Ma was enhanced by IFN-Q treatment
(Fig. 3A,C). These results, which were observed in seven in-
dependent experiments, were consistent with a IFN-Q-depend-
ent upregulation of the class I processing and presentation
pathway [16]. Expression of the proteasome MHC-encoded
subunits, LMP2 and LMP7, in HeLa cells was signi¢cantly
Fig. 2. Puri¢cation, sizing and cytotoxicity of SLT-peptide chimeras.
A: Expression of recombinant SLT fusions. Samples were subjected
to reducing SDS-PAGE and silver staining. E refers to a sample of
total E. coli extract; FT refers to a sample of column £ow through.
The positions of SLT A and B chain are indicated. B: Reducing
SDS-PAGE comparing the apparent molecular weights of SLT
N-Ma and SLT C-Ma A chains with native SLT A chain. C: Toxic-
ity of wild type and D167 SLT-peptide chimeras towards HeLa-A2
cells, and wild type SLT towards SKmel-29 cells. F, wild type SLT
N-Ma; b, E167D SLT N-Ma; E, wild type SLT C-Ma; a, E167D
SLT C-Ma; 8, SK-mel; O, HeLa-A2 cells pre-treated with BFA
for 1 h prior to addition of wild type SLT N-Ma. BFA was main-
tained throughout the toxin incubation and pulse labelling period.
Fig. 3. HeLa-A2 cells incubated with SLT N-Ma are sensitised for
lysis by Matrix 58^66 speci¢c CTL. A: HeLa-A2 cells were incu-
bated overnight with 20 ng/ml of the D167SLT-Ma chimeras. Cells
were then loaded with 51Cr and plated with CTLs at e¡ector/target
ratios of 5:1 (black bars) and 2:1 (white bars) as described in Sec-
tion 2. Where indicated HeLa A2 cells were pre-treated with IFN-Q
for 48 h before the addition of toxin. Controls include HeLa-A2
cells infected for 90 min with vaccinia virus encoding in£uenza Ma-
trix (M1). B: SKmel-29 cells were incubated with SLT N-Ma and
the ability of these cells to be sensitised for cytotoxicity was deter-
mined by using the A2 MAGE-3 peptide 271^279 and HLA-A2
MAGE-3-speci¢c CTLs at e¡ector/target ratios of 27:1 (black bars)
and 9:1 (white bars). C: HeLa-A2 cells were pre-treated with IFN-Q
as described in Section 2 and, where indicated, with BFA for 1 h
before addition of toxin or M1. BFA was maintained at this con-
centration throughout the assay.
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enhanced after incubation with IFN-Q (data not shown), in-
dicating that the class I presentation pathway was indeed
upregulated upon incubation with IFN-Q. To con¢rm that
the M58^66 epitope was generated by intracellular proteases
rather than serum proteases, we used as target cells the mel-
anoma line SKmel-29, which is naturally resistant to SLT
(data not shown). The results of these experiments showed
that SKmel-29, which were killed after pulsing with synthetic
peptides, were not sensitised for lysis after adding the SLT N-
Ma (Fig. 3B).
4. Discussion
In this paper we describe how nanomolar amounts of a
disarmed SLT1 A chain carrying, at its N-terminus, a well
de¢ned peptide epitope for in£uenza virus Matrix protein
can be used to deliver antigen for intracellular processing
and interaction with MHC class I molecules in vitro. This
leads to subsequent surface recognition by CTLs in associa-
tion with MHC class I molecules.
Precisely where in the cell the SLT-Ma chimeras are being
processed (ER or cytosol) remains unclear. It is known that
SLT holotoxin must reach the ER [9,10] where it is then
believed to exploit the ER export machinery normally associ-
ated with the ejection of aberrantly folded ER proteins to the
cytosol for degradation [17,18]. If processing occurs in the
cytosol, this may explain the lack of presentation when using
SLT C-Ma. SLT C-Ma has M58^66 located at the C-terminal
end of the B chain-binding A2 fragment (Fig. 1), a region that
appears not to translocate from the ER to the cytosol. From
studies of CT [8], it appears far more likely that only the N-
terminal A1 fragment of SLT1 (generated by proteolytic
cleavage of holotoxin during endocytosis [19]) is transloca-
tionally competent after its reduction from the A2 fragment
in the ER lumen. Since only SLT N-Ma contains the antigenic
peptide on the toxin A1 fragment, this could explain why SLT
N-Ma rather than SLT C-Ma is capable of being properly
processed. Surprisingly, the proteasomal inhibitor lactacystin
did not block the processing and presentation of Ma from
SLT N-Ma (data not shown), as has also been shown for
the full length in£uenza Matrix protein. This observation sug-
gests that non-proteasomal cytosolic proteases may be in-
volved in the generation of the M58^66 epitope.
Treatment of the cells with the Golgi stack-disrupting agent
BFA successfully blocked the presentation of the M58^66
epitope by HLA-A2 molecules at the cell surface (Fig. 3C).
Toxin uptake is blocked by BFA (Fig. 2C) leading to toxin
accumulation within endosomes where it could conceivably
interact with MHC class I molecules recycling from the cell
surface [20]. The data here however, clearly suggest that the
M58^66 epitope from SLT fusions follows the classical class I
processing pathway (ER to cell surface via the Golgi) and that
its binding to class I molecules does not take place in endo-
somes. Furthermore, the ¢nding that BFA blocks the cytotox-
icities of wild type SLT N-Ma (Fig. 2C) reveals that, upon
endocytosis, the toxin fusions follow the same pathway as
native SLT, a route that involves passage through the Golgi
to the ER for membrane transport, rather than translocation
across endosomal membranes.
Other toxins (diphtheria toxin (DT), anthrax toxin and
Pseudomonas exotoxin A (PE)) have been used to deliver pep-
tide epitopes [21^25] but with one exception [23], the intra-
cellular routing pathway or the location of processing was not
known or investigated. Where DT and anthrax toxin lethal
factor (LF) were used, translocation of the antigenic peptide
presumably occurred from acidi¢ed endosomes, the site of LF
entry into the cytosol, and processing involved cytosolic pro-
teasomes. PE, like SLT-A, is believed to translocate from the
ER, but, unlike SLT, has never been visualised there. Indeed,
where PE was used to deliver peptides, BFA was without
e¡ect on antigen presentation suggesting that a di¡erent in-
ternalisation/processing pathway was being used [22]. Re-
cently, the B chain of a relative of SLT, namely the Shigella
dysenteriae Shiga toxin B chain, has been used to successfully
deliver a peptide antigen from the Mage 1 tumour antigen to
MHC class 1 proteins [26]. As here, processing and presenta-
tion appeared to involve tra⁄cking of toxin chimeras to the
ER of target cells. The B fragment of Shiga toxin is believed
not to translocate to the cytosol from the ER (our unpub-
lished observations) suggesting that processing of the Mage
peptide from the toxin-peptide chimera could occur within
this organelle. SLT holotoxin with its membrane translocating
A chain component may be of greater utility when whole
antigens rather than short peptides are to be delivered. In
these instances, it seems reasonable to anticipate a require-
ment for conventional proteasomal degradation. What re-
mains clear from the present study and that of Lee et al.
[26] is that both subunits of the Shiga toxin class of proteins
can be used to e¡ectively carry very di¡erent antigenic pep-
tides. This is important if such proteins are to ful¢ll their
potential as future T cell vaccines. Moreover, since the ST/
SLT family of toxins are known to reach the ER by endocy-
tosis in amounts that permit visualisation by conventional
methods, it should now be possible to use these proteins to
further probe the MHC class I restricted antigen processing
pathway.
Acknowledgements: This work was supported by a grant from The
Wellcome Trust to L.M.R., J.M.L. and V.C., and a UK MRC senior
fellowship to V.C.
References
[1] Cerundolo, V. and Braud, V. (1996) in: Cell Biology of MHC
Class I Molecules (Browning, M.J. and McMichael, A.J., Eds.),
p. 193, BIOS Scienti¢c, Oxford.
[2] Zinkernagel, R.M., Bachmann, M.F., Kundig, T.M., Oehen, S.,
Pirchet, H. and Hengartner, H. (1996) Annu. Rev. Immunol. 14,
333^367.
[3] Meier, U.C., Klenerman, P., Gri¡en, P., James, W., Koppe, B.,
Larder, B., McMichael, A.J. and Philips, R. (1995) Science 270,
1360^1362.
[4] Romero, P., Dunbar, R., Valmori, D., Pittet, M., Ogg, G., Ri-
moldi, D., Chen, J-L., Lienard, D., Cerottini, J-C. and Cerundo-
lo, V. (1998) J. Exp. Med. 188, 1641^1650.
[5] Bona, C.A., Casares, S. and Brumeanu, T.-D. (1998) Immunol.
Today 126, 126^133.
[6] Fraser, M.E., Chernaia, M.M., Kozlov, Y.V. and James, N.G.
(1994) Struct. Biol. 1, 59^64.
[7] Jacewicz, M., Clausen, H., Nudelman, E., Donohue-Rolfe, A.
and Keusch, G.T. (1986) J. Exp. Med. 163, 1392^1404.
[8] Majoul, I.V., Bastiaens, P.I.H. and Soling, H.-D. (1996) J. Cell
Biol. 133, 777^789.
[9] Sandvig, K., Garred, O., Prytz, K., Kozlov, J.V., Hansen, S.H.
and van Deurs, B. (1992) Nature 358, 510^511.
[10] Sandvig, K., Ryd, M., Garred, O., Schweda, E., Holm, P.K. and
van Deurs, B. (1994) J. Cell Biol. 126, 53^64.
[11] Calderwood, S.B., Acheson, D.W., Goldberg, M.B., Boyko, S.A.
and Donohue-Rolfe, A. (1990) Infect. Immun. 58, 2977^2982.
FEBS 22068 10-6-99
K.L. Noakes et al./FEBS Letters 453 (1999) 95^9998
[12] Dunbar, P.R., Ogg, G.S., Chen, J., Rust, N. and van der Brug-
gen, P. (1998) Curr. Biol. 8, 413^416.
[13] Hovde, C.J., Calderwood, S.B., Mekalnaos, J.J. and Collier, R.J.
(1988) Proc. Natl. Acad. Sci. USA 85, 2568^2572.
[14] May, M.J., Hartley, M.R., Roberts, L.M., Krieg, P.A., Osborn,
R.W. and Lord, J.M. (1989) EMBO J. 8, 301^308.
[15] Cerundolo, V., Anderson, A.J., Lamb, C., Cresswell, P., McMi-
chael, A., Gotch, F. and Townsend, A. (1990) Nature 345, 449^
452.
[16] Yang, Y., Waters, J.B., Fruh, K. and Peterson, P.A. (1992) Proc.
Natl. Acad. Sci. USA 89, 4928^4932.
[17] Lord, J.M. and Roberts, L.M. (1998) J. Cell Biol. 140, 733^736.
[18] Kopito, R.R. (1997) Cell 88, 427^430.
[19] Garred, O., Dubinina, E., Holm, P.K., Olsnes, S., van Deurs, B.
and Kozlov, J.V. (1995) Exp. Cell Res. 218, 39^49.
[20] Reid, P.A. and Watts, C. (1990) Nature 346, 655^657.
[21] Stenmark, H., Moskaug, J.O., Madshus, I.H., Sandvig, K. and
Olsnes, S. (1991) J. Cell Biol. 113, 1025^1032.
[22] Donelly, J.J., Ulmer, J.B., Hawe, L.A., Friedman, A., Shi, X.-P.,
Leander, K.R., Shiver, J.W., Oli¡, A.I., Martinez, D., Montgom-
mery, D. and Liu, M.A. (1993) Proc. Natl. Acad. Sci. USA 90,
3530^3534.
[23] Goletz, T.J., Klimpel, K.R., Arora, N., Leppla, S.H., Keith, J.M.
and Berzofsky, J.A. (1997) Proc. Natl. Acad. Sci. USA 94,
12059^12064.
[24] Ballard, D.J., Collier, R.J. and Starnbach, M.N. (1996) Proc.
Natl. Acad. Sci. USA 93, 12531^12534.
[25] Ballard, J.D., Doling, A.M., Beauregard, K., Collier, R.J. and
Starnbach, M.N. (1998) Infect. Immun. 66, 615^619.
[26] Lee, R-S., Tartour, E., van der Bruggen, P., Vantomme, V., Joy-
eux, I., Goud, B., Fridman, W.H. and Johannes, L. (1998) Eur. J.
Immunol. 28, 2726^2737.
FEBS 22068 10-6-99
K.L. Noakes et al./FEBS Letters 453 (1999) 95^99 99
